Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | ALK over exp |
Therapy | Crizotinib |
Indication/Tumor Type | neuroectodermal tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK over exp | neuroectodermal tumor | predicted - sensitive | Crizotinib | Case Reports/Case Series | Actionable | In a clinical case study, Xalkori (crizotinib) treatment resulted in reduced volume of several metastatic tumors with disease stability lasting 4 years before treatment discontinuation, and continued for at least another 18 months off therapy, in a pediatric patient with metastatic primitive neuroectodermal tumor with ALK overexpression (PMID: 36619485). | 36619485 |
PubMed Id | Reference Title | Details |
---|---|---|
(36619485) | Targeted treatment of refractory primitive neuroectodermal tumor arising from an immature teratoma with crizotinib leading to a sustained response. | Full reference... |